Judge Bars Antitrust Claims in MedImmune's Patent Suit Vs. Genentech

Law360, New York (December 29, 2003, 12:00 AM EST) -- In a case with wide-ranging implications for licensing in the biotechnology sector, a U.S. District Court has ruled that MedImmune cannot pursue antitrust claims in its suit to invalidate a patent controlled by Genentech.

Medimmune had sued Genentech, Celltech, and others, in the U.S. District Court for the Central District of California in April this year, claiming that Genentech and Celltech entered into a collusive, anticompetitive agreement designed to extend the patent monopoly over what Genentech calls "the 'fundamental technology' required for the artificial synthesis of...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.